Hoffmann-la Roche Inc.

Roche Glycart Ag

Sanofi

Bristol-myers Squibb Compnay

Roche Palo Alto LLC

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Sarl

Engmab Beta Holdings LLC

Joerg Thomas Regula

Christian Klein

Wolfgang Schaefer

Sabine Imhof-Jung

Pablo Umana

Michael Molhoj

Ulrich Brinkmann

Werner Scheuer

Anita Kavlie

Juergen Michael Schanzer

Ekkehard Moessner

Stefan Seeber

Stefan Klostermann

Guy Georges

Klaus Kaluza

Hubert Kettenberger

Marina Bacac

Oliver Ast

Peter Bruenker

Tilman Schlothauer

Ulrich Goepfert

Petra Rueger

Kurt Lang

Claudia Ferrara Koller

Sandra Grau-Richards

Stephan Fischer

Kay-Gunnar Stubenrauch

Georg Fertig

Stefan Dengl

Joerg Moelleken

Jens Fischer

Guido Hartmann

Matthias Rueth

Hendrik Knoetgen

Christian Schantz

Gary J Nabel

Erhard Kopetzki

Ralf Hosse

Huawei Qiu

Olaf Mundigl

Ralf Schumacher

Anne Freimoser-Grundschober

Ercole Rao

Klaus-Peter Kuenkele

Béatrice Cameron

Paul Parren

Jan Van De Winkel

Pablo Umaña

Birgit Bossenmaier

Adelbert Grossmann

Yvo Graus

Peter Sondermann

Remko Griep

Harald Duerr

Viktor Levitski

Laurent Lariviere

Maria Amann

Andreas Schaubmar

Christina Claus

Friederike Hesse

Christiane Neumann

Sebastian Fenn

Monika Baehner

Valeria Lifke

Tanja Fauti

Peter Michael Huelsmann

Friedrich Metzger

Christian Beil

Tarik Dabdoubi

Frank Herting

Catherine Prades

Cendrine Lemoine

Ling Xu

Zhi-Yong Yang

Klaus Strein

Samuel Moser

Lan Wu

Jochen Beninga

Rebecca Croasdale

Edward Seung

Christian Gassner

Minh Diem Vu

Barbara Weiser

Joerg Birkenfeld

Jan Olaf Stracke

Sabine Gruener

Martin Lanzendoerfer

Ronnie Rong Wei

Martine Van Vugt

Frank Rebers

Claudio Sustmann

Lydia Jasmin Hanisch

Josef Endl

Apollon Papadimitriou

Maximiliane Koenig

Hans Koll

Sylvia Herter

Manfred Schwaiger

Sebastian Neumann

Wilma Lau

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.

Fc-receptor binding modified asymmetric antibodies and methods of use

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antigen binding proteins

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

Growing community of inventors

Munich, Germany

Joerg Thomas Regula